越来越多的自身免疫性脑炎(Autoimmune encephalitis,AE)患者的资料显示,其临床表现和结局的特异性依赖于患者脑脊液、血清中特定抗原的抗体。这些特异性包括了癫痫相关的临床表现及对抗癫痫药物的反应。虽然学者们对这一类疾病的研究热情不断增加,且发现了新的抗体和相关的临床综合征,但仍有一些问题需要进一步解答。首先,鉴于每一种自身免疫性抗体介导的综合征的严重程度、患者特点、治疗时间不尽相同,治疗需要个体化;其次,缺乏随机对照试验是形成适当的免疫治疗策略的重大障碍。文章就一些已阐明的 AE 患者的癫痫诊断和治疗方面的新进展和挑战作一综述,并阐述在这一新兴领域中合理应用精确药物的原则。
Citation: VogrigAlberto, JoubertBastien, Andre-ObadiaNathalie, 陈邓, 慕洁. 抗体介导的自身免疫性脑炎患者的癫痫特点. Journal of Epilepsy, 2020, 6(3): 235-248. doi: 10.7507/2096-0247.20200043 Copy
1. | Britton J. Autoimmune epilepsy. Handb Clin Neurol, 2016, 133: 219-245. |
2. | Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci, 2015, 1338: 94-114. |
3. | Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol, 2010, 67(3): 330-335. |
4. | Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol, 2012, 8(7): 380-390. |
5. | Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol, 2017, 81(2): 183-192. |
6. | van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol, 2017, 81(2): 193-198. |
7. | Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol, 2015, 22(8): 1151-1161. |
8. | Manto M, Dalmau J, Didelot A, et al. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis, 2010, 5: 31. |
9. | Moscato EH, Peng X, Jain A, et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol, 2014, 76(1): 108-119. |
10. | Petit-Pedrol M, Sell J, Planagumà J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain, 2018, 141(11): 3144-3159. |
11. | Daif A, Lukas RV, Issa NP, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav, 2018, 80: 331-336. |
12. | Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol, 2011, 10(1): 63-74. |
13. | Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol, 2008, 7(12): 1091-1098. |
14. | Gillinder L, Warren N, Hartel G, et al. EEG findings in NMDA encephalitis-A systematic review. Seizure, 2019, 65: 20-24. |
15. | Baykan B, Gungor Tuncer O, Vanli-Yavuz EN, et al. Delta brush pattern is not unique to NMDAR encephalitis: Evaluation of two independent long-term EEG cohorts. Clin EEG Neurosci, 2018, 49(4): 278-284. |
16. | Jeannin-Mayer S, André-Obadia N, Rosenberg S, et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin Neurophysiol, 2019, 130(2): 289-296. |
17. | Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia, 2017, 58(12): 2104-2111. |
18. | de Montmollin E, Demeret S, Brulé N, et al. Anti-N-Methyl-d-Aspartate receptor encephalitis in adult patients requiring intensive care. Am J Respir Crit Care Med, 2017, 195(4): 491-499. |
19. | Titulaer MJ, Mc Cracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013, 12(2): 157-165. |
20. | Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82(7): 556-563. |
21. | Zekeridou A, Karantoni E, Viaccoz A, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol, 2015, 262(8): 1859-1866. |
22. | Sonderen AV, Arends S, Tavy DLJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry, 2018, 89(10): 1101-1106. |
23. | Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology, 2012, 79(11): 1094-1100. |
24. | Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr, 2013, 162(4): 850-856. |
25. | Veciana M, Becerra JL, Fossas P, et al. EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Epilepsy Behav, 2015, 49: 280-285. |
26. | Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol, 2009, 65(4): 424-434. |
27. | Joubert B, Kerschen P, Zekeridou A, et al. Clinical spectrum of encephalitis associated with antibodies against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor: Case series and review of the literature. JAMA Neurol, 2015, 72(10): 1163-1169. |
28. | Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology, 2015, 84(24): 2403-2412. |
29. | Dogan Onugoren M, Deuretzbacher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry, 2015, 86(9): 965-972. |
30. | Nibber A, Clover L, Pettingill P, et al. Antibodies to AMPA receptors in rasmussen's encephalitis. Eur J Paediatr Neurol, 2016, 20(2): 222-227. |
31. | van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology, 2016, 87(14): 1449-1456. |
32. | Navarro V, Kas A, Apartis E, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain, 2016, 139(Pt 4): 1079-1093. |
33. | Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 2010, 133(9): 2734-2748. |
34. | Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede lgi1 antibody limbic encephalitis. Ann Neurol, 2011, 69(5): 892-900. |
35. | Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136(Pt 10): 3151-3162. |
36. | Vogrig A, Pauletto G, Lettieri C, et al. Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis. Neurol Sci, 2019, 40(7): 1503-1505. |
37. | Andrade DM, Tai P, Dalmau J, et al. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology, 2011, 76(15): 1355-1357. |
38. | Naasan G, Irani SR, Bettcher BM, et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol, 2014, 71(10): 1300-1304. |
39. | Steriade C, Mirsattari SM, Murray BJ, et al. Subclinical temporal EEG seizure pattern in LGI1-antibody-mediated encephalitis. Epilepsia, 2016, 57(8): e155-e160. |
40. | Brigo F, Vogrig A, Bratti A, et al. Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case. Epileptic Disord, 2018, 20(4): 301-312. |
41. | Vogrig A, Pauletto G, Belgrado E, et al. Effect of thymectomy on refractory autoimmune status epilepticus. J Neuroimmunol, 2018, 317: 90-94. |
42. | Shin YW, Ahn SJ, Moon J, et al. Increased adverse events associated with antiepileptic drugs in anti-leucine-rich glioma-inactivated protein 1 encephalitis. Epilepsia, 2018, 59(Suppl 2): 108-112. |
43. | Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med, 2011, 364(12): 1126-1133. |
44. | Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428(6982): 486. |
45. | Berghuis B, de Haan GJ, van den Broek MP, et al. Epidemiology, pathophysiology and putative genetic basis of carbamazepine-and oxcarbazepine-induced hyponatremia. Eur J Neurol, 2016, 23(9): 1393-1399. |
46. | Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, Antiepileptic drugs, and aggression: An evidence-based review. Pharmacol Rev, 2016, 68(3): 563-602. |
47. | López-Chiriboga AS, Klein C, Zekeridou A, et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol, 2018, 84(3): 473-480. |
48. | Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol, 2011, 69(2): 303-311. |
49. | Joubert B, Saint-Martin M, Noraz N, et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, Prominent limbic symptoms, and seizures. JAMA Neurol, 2016, 73(9): 1115-1124. |
50. | van Sonderen A, Ariño H, Dalmau J, et al. Author response: The clinical spectrum of Caspr2 antibody-associated disease. Neurology, 2017, 88(3): 333-334. |
51. | Bien CG, Mirzadjanova Z, Baumgartner C, et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol, 2017, 24(1): 175-186. |
52. | Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol, 2013, 73(1): 120-128. |
53. | Hara M, Ariño H, Petit-Pedrol M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology, 2017, 88(14): 1340-1348. |
54. | Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain, 2008, 131(Pt 10): 2553-2563. |
55. | Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol, 2010, 67(4): 470-478. |
56. | Falip M, Carreño M, Miró J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol, 2012, 19(6): 827-833. |
57. | Ariño H, Höftberger R, Gresa-Arribas N, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol, 2015, 72(8): 874-881. |
58. | Mäkelä KM, Hietaharju A, Brander A, et al. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol, 2018, 9: 579. |
59. | Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA(A) receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol, 2014, 13(3): 276-286. |
60. | Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABA. Neurology, 2017, 88(11): 1012-1020. |
61. | Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol, 2010, 9(1): 67-76. |
62. | Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology, 2011, 76(9): 795-800. |
63. | Höftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABA(B) receptor antibodies: novel findings in a new case series of 20 patients. Neurology, 2013, 81(17): 1500-1506. |
64. | Maureille A, Fenouil T, Joubert B, et al. Isolated seizures are a common early feature of paraneoplastic anti-GABA. J Neurol, 2019, 266(1): 195-206. |
65. | Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology, 2008, 71(16): 1291-1292. |
66. | McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol, 2013, 70(1): 44-50. |
67. | Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137(Pt 8): 2178-2192. |
68. | Ude C, Ambegaonkar G. Glycine receptor antibody-associated epilepsy in a boy aged 4 years. BMJ Case Rep, 2010, 2016: pii: bcr2016216468. |
69. | Wuerfel E, Bien CG, Vincent A, et al. Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. J Neurol Sci, 2014, 343(1-2): 180-182. |
70. | Chan DWS, Thomas T, Lim M, et al. Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children. Eur J Paediatr Neurol, 2017, 21(2): 414-417. |
71. | Baysal-Kirac L, Tuzun E, Erdag E, et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. J Neurol, 2016, 263(3): 455-466. |
72. | Nóbrega-Jr AW, Gregory CP, Schlindwein-Zanini R, et al. Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies. Epilepsia, 2018, 59(9): e152-e156. |
73. | Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54(6): 1028-1035. |
74. | Ekizoglu E, Tuzun E, Woodhall M, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55(3): 414-422. |
75. | Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the ophelia syndrome. Neurology, 2011, 77(18): 1698-1701. |
76. | Prüss H, Rothkirch M, Kopp U, et al. Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology, 2014, 83(15): 1384-1386. |
77. | Mat A, Adler H, Merwick A, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology, 2013, 80(14): 1349-1350. |
78. | Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology, 2018, 90(22): e1964-e1972. |
79. | Gresa-Arribas N, Planagumà J, Petit-Pedrol M, et al. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology, 2016, 86(24): 2235-2242. |
80. | Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology, 2018, 90(21): e1858-e1869. |
81. | Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol, 2019, 15(2): 89-102. |
82. | Ramanathan S, O'grady GL, Malone S, et al. Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol, 2019, 61(5): 610-614. |
83. | Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4(2): e322. |
84. | Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol, 2018, 75(1): 65-71. |
85. | Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404. |
86. | Vogrig A, Joubert B, Ducray F, et al. Glioblastoma as differential diagnosis of autoimmune encephalitis. J Neurol, 2018, 265(3): 669-677. |
87. | Vogrig A, Brigo F, Valente M, et al. Epidemiology of autoimmune versus infectious encephalitis. Ann Neurol, 2018, 83(5): 1037. |
88. | Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58(7): 1181-1189. |
89. | Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia, 2018, 59(4): 739-744. |
90. | Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia, 2018, 59(4): 745-752. |
91. | Caputo D, Iorio R, Vigevano F, et al. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA. Eur J Paediatr Neurol, 2018, 22(1): 182-185. |
92. | Bien CG, Holtkamp M. "Autoimmune Epilepsy": Encephalitis with autoantibodies for epileptologists. Epilepsy Curr, 2017, 17(3): 134-141. |
93. | Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol, 2018, 25(8): 1011-1016. |
94. | Jun JS, Lee ST, Kim R, et al. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol, 2018, 84(6): 940-945. |
95. | Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, et al. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure, 2018, 59: 72-76. |
96. | Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4(4): e353. |
97. | de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA. Neurology, 2019, 92(19): e2185-e2196. |
98. | Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure, 2000, 9(7): 464-468. |
99. | Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the american epilepsy society. Epilepsy Curr, 2016, 16(1): 48-61. |
- 1. Britton J. Autoimmune epilepsy. Handb Clin Neurol, 2016, 133: 219-245.
- 2. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci, 2015, 1338: 94-114.
- 3. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol, 2010, 67(3): 330-335.
- 4. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol, 2012, 8(7): 380-390.
- 5. Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated with unique HLA subtypes. Ann Neurol, 2017, 81(2): 183-192.
- 6. van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol, 2017, 81(2): 193-198.
- 7. Huijbers MG, Querol LA, Niks EH, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol, 2015, 22(8): 1151-1161.
- 8. Manto M, Dalmau J, Didelot A, et al. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis, 2010, 5: 31.
- 9. Moscato EH, Peng X, Jain A, et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol, 2014, 76(1): 108-119.
- 10. Petit-Pedrol M, Sell J, Planagumà J, et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain, 2018, 141(11): 3144-3159.
- 11. Daif A, Lukas RV, Issa NP, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav, 2018, 80: 331-336.
- 12. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol, 2011, 10(1): 63-74.
- 13. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol, 2008, 7(12): 1091-1098.
- 14. Gillinder L, Warren N, Hartel G, et al. EEG findings in NMDA encephalitis-A systematic review. Seizure, 2019, 65: 20-24.
- 15. Baykan B, Gungor Tuncer O, Vanli-Yavuz EN, et al. Delta brush pattern is not unique to NMDAR encephalitis: Evaluation of two independent long-term EEG cohorts. Clin EEG Neurosci, 2018, 49(4): 278-284.
- 16. Jeannin-Mayer S, André-Obadia N, Rosenberg S, et al. EEG analysis in anti-NMDA receptor encephalitis: Description of typical patterns. Clin Neurophysiol, 2019, 130(2): 289-296.
- 17. Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia, 2017, 58(12): 2104-2111.
- 18. de Montmollin E, Demeret S, Brulé N, et al. Anti-N-Methyl-d-Aspartate receptor encephalitis in adult patients requiring intensive care. Am J Respir Crit Care Med, 2017, 195(4): 491-499.
- 19. Titulaer MJ, Mc Cracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 2013, 12(2): 157-165.
- 20. Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82(7): 556-563.
- 21. Zekeridou A, Karantoni E, Viaccoz A, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol, 2015, 262(8): 1859-1866.
- 22. Sonderen AV, Arends S, Tavy DLJ, et al. Predictive value of electroencephalography in anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry, 2018, 89(10): 1101-1106.
- 23. Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology, 2012, 79(11): 1094-1100.
- 24. Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr, 2013, 162(4): 850-856.
- 25. Veciana M, Becerra JL, Fossas P, et al. EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Epilepsy Behav, 2015, 49: 280-285.
- 26. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol, 2009, 65(4): 424-434.
- 27. Joubert B, Kerschen P, Zekeridou A, et al. Clinical spectrum of encephalitis associated with antibodies against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor: Case series and review of the literature. JAMA Neurol, 2015, 72(10): 1163-1169.
- 28. Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology, 2015, 84(24): 2403-2412.
- 29. Dogan Onugoren M, Deuretzbacher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry, 2015, 86(9): 965-972.
- 30. Nibber A, Clover L, Pettingill P, et al. Antibodies to AMPA receptors in rasmussen's encephalitis. Eur J Paediatr Neurol, 2016, 20(2): 222-227.
- 31. van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology, 2016, 87(14): 1449-1456.
- 32. Navarro V, Kas A, Apartis E, et al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain, 2016, 139(Pt 4): 1079-1093.
- 33. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain, 2010, 133(9): 2734-2748.
- 34. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede lgi1 antibody limbic encephalitis. Ann Neurol, 2011, 69(5): 892-900.
- 35. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain, 2013, 136(Pt 10): 3151-3162.
- 36. Vogrig A, Pauletto G, Lettieri C, et al. Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis. Neurol Sci, 2019, 40(7): 1503-1505.
- 37. Andrade DM, Tai P, Dalmau J, et al. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology, 2011, 76(15): 1355-1357.
- 38. Naasan G, Irani SR, Bettcher BM, et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol, 2014, 71(10): 1300-1304.
- 39. Steriade C, Mirsattari SM, Murray BJ, et al. Subclinical temporal EEG seizure pattern in LGI1-antibody-mediated encephalitis. Epilepsia, 2016, 57(8): e155-e160.
- 40. Brigo F, Vogrig A, Bratti A, et al. Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case. Epileptic Disord, 2018, 20(4): 301-312.
- 41. Vogrig A, Pauletto G, Belgrado E, et al. Effect of thymectomy on refractory autoimmune status epilepticus. J Neuroimmunol, 2018, 317: 90-94.
- 42. Shin YW, Ahn SJ, Moon J, et al. Increased adverse events associated with antiepileptic drugs in anti-leucine-rich glioma-inactivated protein 1 encephalitis. Epilepsia, 2018, 59(Suppl 2): 108-112.
- 43. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med, 2011, 364(12): 1126-1133.
- 44. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428(6982): 486.
- 45. Berghuis B, de Haan GJ, van den Broek MP, et al. Epidemiology, pathophysiology and putative genetic basis of carbamazepine-and oxcarbazepine-induced hyponatremia. Eur J Neurol, 2016, 23(9): 1393-1399.
- 46. Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, Antiepileptic drugs, and aggression: An evidence-based review. Pharmacol Rev, 2016, 68(3): 563-602.
- 47. López-Chiriboga AS, Klein C, Zekeridou A, et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol, 2018, 84(3): 473-480.
- 48. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol, 2011, 69(2): 303-311.
- 49. Joubert B, Saint-Martin M, Noraz N, et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, Prominent limbic symptoms, and seizures. JAMA Neurol, 2016, 73(9): 1115-1124.
- 50. van Sonderen A, Ariño H, Dalmau J, et al. Author response: The clinical spectrum of Caspr2 antibody-associated disease. Neurology, 2017, 88(3): 333-334.
- 51. Bien CG, Mirzadjanova Z, Baumgartner C, et al. Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol, 2017, 24(1): 175-186.
- 52. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol, 2013, 73(1): 120-128.
- 53. Hara M, Ariño H, Petit-Pedrol M, et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology, 2017, 88(14): 1340-1348.
- 54. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain, 2008, 131(Pt 10): 2553-2563.
- 55. Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol, 2010, 67(4): 470-478.
- 56. Falip M, Carreño M, Miró J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol, 2012, 19(6): 827-833.
- 57. Ariño H, Höftberger R, Gresa-Arribas N, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol, 2015, 72(8): 874-881.
- 58. Mäkelä KM, Hietaharju A, Brander A, et al. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: The interplay between immunotherapy and anti-epileptic drugs. Front Neurol, 2018, 9: 579.
- 59. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA(A) receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol, 2014, 13(3): 276-286.
- 60. Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABA. Neurology, 2017, 88(11): 1012-1020.
- 61. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol, 2010, 9(1): 67-76.
- 62. Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology, 2011, 76(9): 795-800.
- 63. Höftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABA(B) receptor antibodies: novel findings in a new case series of 20 patients. Neurology, 2013, 81(17): 1500-1506.
- 64. Maureille A, Fenouil T, Joubert B, et al. Isolated seizures are a common early feature of paraneoplastic anti-GABA. J Neurol, 2019, 266(1): 195-206.
- 65. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology, 2008, 71(16): 1291-1292.
- 66. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol, 2013, 70(1): 44-50.
- 67. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137(Pt 8): 2178-2192.
- 68. Ude C, Ambegaonkar G. Glycine receptor antibody-associated epilepsy in a boy aged 4 years. BMJ Case Rep, 2010, 2016: pii: bcr2016216468.
- 69. Wuerfel E, Bien CG, Vincent A, et al. Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. J Neurol Sci, 2014, 343(1-2): 180-182.
- 70. Chan DWS, Thomas T, Lim M, et al. Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children. Eur J Paediatr Neurol, 2017, 21(2): 414-417.
- 71. Baysal-Kirac L, Tuzun E, Erdag E, et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. J Neurol, 2016, 263(3): 455-466.
- 72. Nóbrega-Jr AW, Gregory CP, Schlindwein-Zanini R, et al. Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies. Epilepsia, 2018, 59(9): e152-e156.
- 73. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013, 54(6): 1028-1035.
- 74. Ekizoglu E, Tuzun E, Woodhall M, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia, 2014, 55(3): 414-422.
- 75. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the ophelia syndrome. Neurology, 2011, 77(18): 1698-1701.
- 76. Prüss H, Rothkirch M, Kopp U, et al. Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology, 2014, 83(15): 1384-1386.
- 77. Mat A, Adler H, Merwick A, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology, 2013, 80(14): 1349-1350.
- 78. Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology, 2018, 90(22): e1964-e1972.
- 79. Gresa-Arribas N, Planagumà J, Petit-Pedrol M, et al. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology, 2016, 86(24): 2235-2242.
- 80. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study. Neurology, 2018, 90(21): e1858-e1869.
- 81. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol, 2019, 15(2): 89-102.
- 82. Ramanathan S, O'grady GL, Malone S, et al. Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. Dev Med Child Neurol, 2019, 61(5): 610-614.
- 83. Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4(2): e322.
- 84. Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol, 2018, 75(1): 65-71.
- 85. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol, 2016, 15(4): 391-404.
- 86. Vogrig A, Joubert B, Ducray F, et al. Glioblastoma as differential diagnosis of autoimmune encephalitis. J Neurol, 2018, 265(3): 669-677.
- 87. Vogrig A, Brigo F, Valente M, et al. Epidemiology of autoimmune versus infectious encephalitis. Ann Neurol, 2018, 83(5): 1037.
- 88. Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58(7): 1181-1189.
- 89. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia, 2018, 59(4): 739-744.
- 90. Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia, 2018, 59(4): 745-752.
- 91. Caputo D, Iorio R, Vigevano F, et al. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA. Eur J Paediatr Neurol, 2018, 22(1): 182-185.
- 92. Bien CG, Holtkamp M. "Autoimmune Epilepsy": Encephalitis with autoantibodies for epileptologists. Epilepsy Curr, 2017, 17(3): 134-141.
- 93. Graus F, Escudero D, Oleaga L, et al. Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol, 2018, 25(8): 1011-1016.
- 94. Jun JS, Lee ST, Kim R, et al. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol, 2018, 84(6): 940-945.
- 95. Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, et al. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure, 2018, 59: 72-76.
- 96. Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm, 2017, 4(4): e353.
- 97. de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA. Neurology, 2019, 92(19): e2185-e2196.
- 98. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure, 2000, 9(7): 464-468.
- 99. Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the american epilepsy society. Epilepsy Curr, 2016, 16(1): 48-61.
-
Previous Article
免疫性癫痫研究进展 -
Next Article
2017年国际抗癫痫联盟癫痫分类评论